CINGW
Price:
$0.0413
Market Cap:
$15.16M
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
CINGW
According to Cingulate Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 5.36M. This represents a change of 15.45% compared to the average of 4.64M of the last 4 quarters.
The mean historical Enterprise Value of Cingulate Inc. over the last ten years is 28.05M. The current 5.36M Enterprise Value has changed 1.81% with respect to the historical average. Over the past ten years (40 quarters), CINGW's Enterprise Value was at its highest in in the March 2021 quarter at 51.52M. The Enterprise Value was at its lowest in in the September 2024 quarter at -903510.52.
Average
28.05M
Median
15.60M
Minimum
10.01M
Maximum
52.00M
Discovering the peaks and valleys of Cingulate Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Enterprise Value = 52.00M
Minimum Annual Increase = -69.51%
Minimum Annual Enterprise Value = 10.01M
Year | Enterprise Value | Change |
---|---|---|
2023 | 10.01M | -12.82% |
2022 | 11.48M | -26.42% |
2021 | 15.60M | -69.51% |
2020 | 51.18M | -1.58% |
The current Enterprise Value of Cingulate Inc. (CINGW) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
12.36M
5-year avg
28.05M
10-year avg
28.05M
Cingulate Inc.’s Enterprise Value is less than Cingulate Inc. (5.36M), less than Celularity Inc. (91.87M), less than NeuroSense Therapeutics Ltd. (16.35M), less than EQRx, Inc. (826.94M), greater than Dermata Therapeutics, Inc. (-3823196.00),
Company | Enterprise Value | Market cap |
---|---|---|
5.36M | $15.16M | |
91.87M | $93.64M | |
16.35M | $10.92M | |
826.94M | $1.14B | |
-3823196.00 | $2.96M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cingulate Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cingulate Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Cingulate Inc.'s Enterprise Value?
What is the highest Enterprise Value for Cingulate Inc. (CINGW)?
What is the 3-year average Enterprise Value for Cingulate Inc. (CINGW)?
What is the 5-year average Enterprise Value for Cingulate Inc. (CINGW)?
How does the current Enterprise Value for Cingulate Inc. (CINGW) compare to its historical average?